What is HC Wainwright’s Estimate for BTAI Q1 Earnings?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) – Research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for BioXcel Therapeutics in a report issued on Thursday, April 2nd. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings per share of ($0.31) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for BioXcel Therapeutics’ current full-year earnings is ($24.39) per share. HC Wainwright also issued estimates for BioXcel Therapeutics’ Q2 2027 earnings at ($0.29) EPS, Q3 2027 earnings at ($0.26) EPS and Q4 2027 earnings at ($0.26) EPS.

BTAI has been the subject of several other reports. Wall Street Zen raised shares of BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a report on Wednesday, January 21st. Zacks Research upgraded BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Rodman & Renshaw started coverage on BioXcel Therapeutics in a report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price on the stock. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioXcel Therapeutics currently has a consensus rating of “Hold” and an average price target of $11.00.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $1.18 on Friday. The company has a 50-day moving average of $1.54 and a 200-day moving average of $1.91. The firm has a market cap of $31.95 million, a price-to-earnings ratio of -0.18 and a beta of 0.30. BioXcel Therapeutics has a twelve month low of $1.08 and a twelve month high of $8.08.

BioXcel Therapeutics (NASDAQ:BTAI) last issued its quarterly earnings results on Friday, March 27th. The company reported ($0.58) EPS for the quarter, hitting the consensus estimate of ($0.58). The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.15 million.

Institutional Investors Weigh In On BioXcel Therapeutics

Large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. purchased a new stake in shares of BioXcel Therapeutics in the 1st quarter valued at approximately $50,000. Geode Capital Management LLC grew its position in BioXcel Therapeutics by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after purchasing an additional 6,120 shares in the last quarter. XTX Topco Ltd purchased a new position in BioXcel Therapeutics during the 2nd quarter worth approximately $42,000. Oaktree Capital Management LP acquired a new stake in BioXcel Therapeutics during the 2nd quarter valued at $437,000. Finally, Oaktree Fund Advisors LLC acquired a new stake in BioXcel Therapeutics during the 2nd quarter valued at $78,000. Institutional investors and hedge funds own 30.68% of the company’s stock.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.